These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

385 related items for PubMed ID: 17920584

  • 1. Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects.
    Ushiyama S, Yamada T, Murakami Y, Kumakura S, Inoue S, Suzuki K, Nakao A, Kawara A, Kimura T.
    Eur J Pharmacol; 2008 Jan 06; 578(1):76-86. PubMed ID: 17920584
    [Abstract] [Full Text] [Related]

  • 2. Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.
    Gierse JK, Zhang Y, Hood WF, Walker MC, Trigg JS, Maziasz TJ, Koboldt CM, Muhammad JL, Zweifel BS, Masferrer JL, Isakson PC, Seibert K.
    J Pharmacol Exp Ther; 2005 Mar 06; 312(3):1206-12. PubMed ID: 15494548
    [Abstract] [Full Text] [Related]

  • 3. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
    Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R, Gresser M, Guay J, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O'Neill GP, Ouellet M, Patrick D, Percival MD, Perrier H, Prasit P, Rodger I.
    J Pharmacol Exp Ther; 1999 Aug 06; 290(2):551-60. PubMed ID: 10411562
    [Abstract] [Full Text] [Related]

  • 4. Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2.
    King JN, Dawson J, Esser RE, Fujimoto R, Kimble EF, Maniara W, Marshall PJ, O'Byrne L, Quadros E, Toutain PL, Lees P.
    J Vet Pharmacol Ther; 2009 Feb 06; 32(1):1-17. PubMed ID: 19161451
    [Abstract] [Full Text] [Related]

  • 5. ABT-963 [2-(3,4-difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], a highly potent and selective disubstituted pyridazinone cyclooxgenase-2 inhibitor.
    Harris RR, Black L, Surapaneni S, Kolasa T, Majest S, Namovic MT, Grayson G, Komater V, Wilcox D, King L, Marsh K, Jarvis MF, Nuss M, Nellans H, Pruesser L, Reinhart GA, Cox B, Jacobson P, Stewart A, Coghlan M, Carter G, Bell RL.
    J Pharmacol Exp Ther; 2004 Dec 06; 311(3):904-12. PubMed ID: 15277581
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of COX-1/COX-2 selectivity and potency of a new class of COX-2 inhibitors.
    Gierse J, Nickols M, Leahy K, Warner J, Zhang Y, Cortes-Burgos L, Carter J, Seibert K, Masferrer J.
    Eur J Pharmacol; 2008 Jun 24; 588(1):93-8. PubMed ID: 18457826
    [Abstract] [Full Text] [Related]

  • 7. The anti-inflammatory effects of ZLJ-6, a novel dual cyclooxygenase/5-lipoxygenase inhibitor.
    Li L, Ji H, Sheng L, Zhang Y, Lai Y, Chen X.
    Eur J Pharmacol; 2009 Apr 01; 607(1-3):244-50. PubMed ID: 19243697
    [Abstract] [Full Text] [Related]

  • 8. Ulcerogenic influence of selective cyclooxygenase-2 inhibitors in the rat stomach with adjuvant-induced arthritis.
    Kato S, Ogawa Y, Kanatsu K, Okayama M, Watanabe T, Arakawa T, Takeuchi K.
    J Pharmacol Exp Ther; 2002 Nov 01; 303(2):503-9. PubMed ID: 12388629
    [Abstract] [Full Text] [Related]

  • 9. Differences in the sensitivity of behavioural measures of pain to the selectivity of cyclo-oxygenase inhibitors.
    Huntjens DR, Spalding DJ, Danhof M, Della Pasqua OE.
    Eur J Pain; 2009 May 01; 13(5):448-57. PubMed ID: 18774319
    [Abstract] [Full Text] [Related]

  • 10. Preclinical pharmacokinetic and pharmacodynamic evaluation of thiazolidinone PG15: an anti-inflammatory candidate.
    Uchôa Fde T, da Silva TG, de Lima Mdo C, Galdino SL, Pitta Ida R, Dalla Costa T.
    J Pharm Pharmacol; 2009 Mar 01; 61(3):339-45. PubMed ID: 19222906
    [Abstract] [Full Text] [Related]

  • 11. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.
    Riendeau D, Percival MD, Brideau C, Charleson S, Dubé D, Ethier D, Falgueyret JP, Friesen RW, Gordon R, Greig G, Guay J, Mancini J, Ouellet M, Wong E, Xu L, Boyce S, Visco D, Girard Y, Prasit P, Zamboni R, Rodger IW, Gresser M, Ford-Hutchinson AW, Young RN, Chan CC.
    J Pharmacol Exp Ther; 2001 Feb 01; 296(2):558-66. PubMed ID: 11160644
    [Abstract] [Full Text] [Related]

  • 12. Effect of celecoxib, a cyclooxygenase-2 inhibitor, on the pathophysiology of adjuvant arthritis in rat.
    Noguchi M, Kimoto A, Kobayashi S, Yoshino T, Miyata K, Sasamata M.
    Eur J Pharmacol; 2005 Apr 25; 513(3):229-35. PubMed ID: 15862805
    [Abstract] [Full Text] [Related]

  • 13. Pharmacological profile of FK881(ASP6537), a novel potent and selective cyclooxygenase-1 inhibitor.
    Imanishi J, Morita Y, Yoshimi E, Kuroda K, Masunaga T, Yamagami K, Kuno M, Hamachi E, Aoki S, Takahashi F, Nakamura K, Miyata S, Ohkubo Y, Mutoh S.
    Biochem Pharmacol; 2011 Oct 01; 82(7):746-54. PubMed ID: 21745460
    [Abstract] [Full Text] [Related]

  • 14. Mathematical analysis of involvement ratio between central and peripheral COX-2 in rat pain models with two types of COX-2 inhibitors with different distribution, celecoxib and CIAA.
    Okumura T, Sakakibara A, Murata Y, Kita Y.
    Eur J Pharmacol; 2008 Jan 06; 578(1):97-9. PubMed ID: 17716650
    [Abstract] [Full Text] [Related]

  • 15. Suppression of adjuvant-induced arthritic bone destruction by cyclooxygenase-2 selective agents with and without inhibitory potency against carbonic anhydrase II.
    Katagiri M, Ogasawara T, Hoshi K, Chikazu D, Kimoto A, Noguchi M, Sasamata M, Harada S, Akama H, Tazaki H, Chung UI, Takato T, Nakamura K, Kawaguchi H.
    J Bone Miner Res; 2006 Feb 06; 21(2):219-27. PubMed ID: 16418777
    [Abstract] [Full Text] [Related]

  • 16. The effects of intrathecal cyclooxygenase-1, cyclooxygenase-2, or nonselective inhibitors on pain behavior and spinal Fos-like immunoreactivity.
    Lee IO, Seo Y.
    Anesth Analg; 2008 Mar 06; 106(3):972-7, table of contents. PubMed ID: 18292448
    [Abstract] [Full Text] [Related]

  • 17. Selective inhibition of COX-2 by a standardized CO2 extract of Humulus lupulus in vitro and its activity in a mouse model of zymosan-induced arthritis.
    Hougee S, Faber J, Sanders A, Berg WB, Garssen J, Smit HF, Hoijer MA.
    Planta Med; 2006 Feb 06; 72(3):228-33. PubMed ID: 16534727
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of 2 celecoxib derivatives: analgesic effect and selectivity to cyclooxygenase-2/1.
    Lu ZH, Xiong XY, Zhang BL, Lin GC, Shi YX, Liu ZG, Meng JR, Zhou YM, Mei QB.
    Acta Pharmacol Sin; 2005 Dec 06; 26(12):1505-11. PubMed ID: 16297351
    [Abstract] [Full Text] [Related]

  • 19. The analgesic actions of centrally administered celecoxib are mediated by endogenous opioids.
    Rezende RM, Dos Reis WG, Duarte ID, Lima PP, Bakhle YS, de Francischi JN.
    Pain; 2009 Mar 06; 142(1-2):94-100. PubMed ID: 19186002
    [Abstract] [Full Text] [Related]

  • 20. Co-administration of rofecoxib and tramadol results in additive or sub-additive interaction during arthritic nociception in rat.
    García-Hernández L, Déciga-Campos M, Guevara-López U, López-Muñoz FJ.
    Pharmacol Biochem Behav; 2007 Mar 06; 87(3):331-40. PubMed ID: 17570478
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.